JP2015517580A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517580A5
JP2015517580A5 JP2015514233A JP2015514233A JP2015517580A5 JP 2015517580 A5 JP2015517580 A5 JP 2015517580A5 JP 2015514233 A JP2015514233 A JP 2015514233A JP 2015514233 A JP2015514233 A JP 2015514233A JP 2015517580 A5 JP2015517580 A5 JP 2015517580A5
Authority
JP
Japan
Prior art keywords
fluorophenyl
pyrazolo
methanone
hexahydro
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514233A
Other languages
English (en)
Japanese (ja)
Other versions
JP6172871B2 (ja
JP2015517580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042732 external-priority patent/WO2013177559A2/en
Publication of JP2015517580A publication Critical patent/JP2015517580A/ja
Publication of JP2015517580A5 publication Critical patent/JP2015517580A5/ja
Application granted granted Critical
Publication of JP6172871B2 publication Critical patent/JP6172871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514233A 2012-05-25 2013-05-24 ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子 Active JP6172871B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US61/651,669 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US61/691,083 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US61/715,907 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US61/759,520 2013-02-01
US201361781629P 2013-03-14 2013-03-14
US61/781,629 2013-03-14
PCT/US2013/042732 WO2013177559A2 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2015517580A JP2015517580A (ja) 2015-06-22
JP2015517580A5 true JP2015517580A5 (enExample) 2016-06-23
JP6172871B2 JP6172871B2 (ja) 2017-08-02

Family

ID=49624542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514233A Active JP6172871B2 (ja) 2012-05-25 2013-05-24 ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子

Country Status (24)

Country Link
EP (6) EP2854814B1 (enExample)
JP (1) JP6172871B2 (enExample)
KR (1) KR102062640B1 (enExample)
CN (1) CN104619328B (enExample)
AU (1) AU2013266110C1 (enExample)
BR (1) BR112014028857B1 (enExample)
CA (1) CA2872260C (enExample)
CL (1) CL2014003173A1 (enExample)
DK (5) DK3851107T3 (enExample)
ES (5) ES2930298T3 (enExample)
FI (1) FI4119561T3 (enExample)
HK (1) HK1250014B (enExample)
IL (1) IL235868A (enExample)
MX (1) MX365423B (enExample)
MY (1) MY172739A (enExample)
NZ (1) NZ701469A (enExample)
PE (1) PE20150352A1 (enExample)
PH (1) PH12014502584A1 (enExample)
PL (5) PL2854814T3 (enExample)
PT (5) PT4119561T (enExample)
RU (1) RU2639867C2 (enExample)
SG (1) SG11201407682TA (enExample)
WO (1) WO2013177559A2 (enExample)
ZA (1) ZA201408182B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX368167B (es) 2013-11-25 2019-09-23 Corcept Therapeutics Inc Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
PH12017502099B1 (en) 2015-05-18 2023-08-30 Corcept Therapeutics Inc Methods for diagnosing and assessing treatment for cushing's syndrome
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
JP6847120B2 (ja) * 2016-03-01 2021-03-24 コーセプト セラピューティクス, インコーポレイテッド チェックポイントインヒビターを強化するためのグルココルチコイドレセプターモジュレーターの使用
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
ES3038908T3 (en) * 2018-04-23 2025-10-15 Corcept Therapeutics Inc Methods of preparing regioselective n-alkyl triazoles
WO2020097513A1 (en) * 2018-11-09 2020-05-14 Corcept Therapeutics Incorporated Methods for shrinking pituitary tumors
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
AU2019405771B2 (en) * 2018-12-20 2025-02-20 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12440487B2 (en) 2019-10-16 2025-10-14 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CA3162636A1 (en) 2019-12-21 2021-06-24 Andreas G. MORAITIS Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
MX2022009781A (es) * 2020-02-10 2022-09-09 Corcept Therapeutics Inc Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides.
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
KR20250073629A (ko) * 2022-10-06 2025-05-27 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제의 제형
EP4608402A1 (en) 2022-10-28 2025-09-03 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
KR20250144469A (ko) * 2023-02-17 2025-10-10 코어셉트 쎄라퓨틱스 인코포레이티드 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
ES2313317T3 (es) 2004-03-09 2009-03-01 Corcept Therapeutics, Inc. Moduladores del receptor de glucocorticoides de azadecalina de anillo condensado.
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2012027702A1 (en) * 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators

Similar Documents

Publication Publication Date Title
JP2015517580A5 (enExample)
RU2014152625A (ru) Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов
RU2457207C2 (ru) Активаторы глюкокиназы
JP2010533158A5 (enExample)
JP2008501673A5 (enExample)
JP2018535999A5 (enExample)
RU2018143324A (ru) Применение 1H-пиразоло[4,3-b]пиридинов в качестве ингибиторов PDE1
JP2007523905A5 (enExample)
JP2007523142A5 (enExample)
JP2009536196A5 (enExample)
JP2006503009A5 (enExample)
CA2747419A1 (en) Sulfonamide derivatives
IL196129A (en) Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis
RU2004121029A (ru) Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1)
JP2013517264A5 (enExample)
JP2007519735A5 (enExample)
JP2014518214A5 (enExample)
HRP20191327T1 (hr) 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
JP2017532364A5 (enExample)
JP2017500364A5 (enExample)
JP2019516737A5 (enExample)
JP2014523400A5 (enExample)
RU2017118562A (ru) Соединения-антагонисты дофаминового d3-рецептора